Why neuromodulation matters in chronic pain
Chronic pain is not merely 'a symptom': it frequently represents a network state (maladaptive plasticity in sensory, affective and descending modulatory circuits). This is where non-invasive neuromodulation offers clinical value: it does not replace exercise, pain education and medical management, but can reduce pain burden and facilitate the patient's return to movement, sleep and graded activity. The key clinical message: effects are typically modest-to-moderate, depend on pain phenotype (neuropathic vs nociplastic) and require adequate dosing and, in some cases, maintenance.
For families: if your relative has chronic pain that hasn't improved sufficiently with standard treatments, this guide explains which brain stimulation techniques exist, which pain types respond best and what to realistically expect.
Available techniques for pain and how they differ
- rTMS (magnetic) — classic target: primary motor cortex M1: In pain management, the most extensively studied target is contralateral M1 (particularly for neuropathic pain). Common protocols: high-frequency (e.g., 10 Hz), multiple sessions over 1–2 weeks; some trials incorporate weekly maintenance. The analgesic mechanism is attributed to network effects (descending modulation and connected circuits), not a purely local M1 phenomenon.
- tDCS (electrical) — accessible and combinable: Typically applied over M1 or DLPFC depending on the therapeutic target (pain vs affect/rumination). Extensively studied in fibromyalgia and explored in migraine and neuropathic pain. Strengths: accessibility, lower cost, potential for supervised domiciliary protocols.
- tACS (alternating current): For pain applications, tACS remains in a more experimental phase: it aims to modulate oscillatory rhythms and cerebral connectivity. Protocol standardisation is less advanced than for tDCS/rTMS in pain.
2024–2026 evidence by pain syndrome
- Peripheral neuropathic pain: Recent sham-controlled trials have examined neuronavigated rTMS over M1 for upper limb neuropathic pain using induction + maintenance schedules. Clinical message: rTMS can provide analgesia, but the effect typically requires multiple sessions and sometimes maintenance.
- Central post-stroke pain (CPSP): A recent systematic review/meta-analysis suggests that TMS can alleviate pain in CPSP and improve selected functional parameters, though effect sizes and outcomes are variable.
- Fibromyalgia (nociplastic pain): 2024 meta-analysis: tDCS reduces pain intensity and may improve fibromyalgia impact and associated symptoms; favourable safety profile reported. A 2025 umbrella review concluded that tDCS may be effective in fibromyalgia with signals in migraine and certain neuropathic conditions, but cautioned that many prior reviews have critically low methodological quality.
- 'Beyond M1' — network targets: A 2025 review in Pain Medicine discusses how M1-attributed efficacy likely derives from effects on connected circuits, opening the path to alternative targets and treatment individualisation.
Clinical selection: who is a good candidate
- Typical candidates: Neuropathic pain (peripheral or central) with partial refractoriness to standard treatment, particularly with signs of central sensitisation and a clear neuropathic phenotype. Fibromyalgia with high pain burden + affective symptoms/fatigue where a tDCS protocol can serve as adjunctive therapy to improve activity capacity and facilitate graded exercise.
- When to exercise particular caution: Pain with red flags (infection, tumour, fracture, progressive neurological deficit). Uncontrolled epilepsy or elevated seizure risk (particularly relevant for rTMS; mandatory screening). Patient without a rehabilitation plan: neuromodulation 'alone' typically yields fragile improvements.
Safety and adverse events
- tES (tDCS/tACS): updated guidelines 2017–2025: Updated safety guidelines for low-intensity tES (2017–2025) provide expert recommendations on risks, special populations and monitoring. Typical adverse events: tingling, pruritus, skin erythema, mild headache (usually self-limiting).
- rTMS: Typical effects: headache, local discomfort, fatigue. Rare but relevant risk: seizure (low incidence, but mandates screening and emergency protocols).
Practical protocols by technique
- rTMS M1 (neuropathic pain) — typical protocol: Induction: 5–10 sessions (daily or near-daily) over 1–2 weeks. Maintenance: weekly or fortnightly if response is achieved with rapid relapse. Discharge criteria: clinically relevant reduction in NRS/VAS + functional improvement (sleep, gait, activity).
- tDCS (fibromyalgia / nociplastic pain): Initial block: 10–20 sessions (per protocol) with MCID assessment and associated symptom evaluation (depression, functional impact). Mandatory integration: graded exercise + pain education; without this, effects tend to be 'lost' in adherence and real-world function.
Comparative table: technique by pain phenotype
Integration with exercise, education and interdisciplinary management
- Neuromodulation + graded exercise: Neuromodulation reduces pain burden → the patient can move more → exercise consolidates improvement (neuroplasticity, sleep, mood). Without exercise, effects tend to be more fragile and less durable.
- Pain education + psychology: Understanding that chronic pain does not always equal tissue damage reduces catastrophising and kinesiophobia. Pain psychology provides coping strategies. The complete model: neuromodulation + exercise + education + psychology.
Evidence Sources
Fuentes
- Sham-controlled trial with neuronavigated rTMS over M1 for upper limb neuropathic pain (Nature, 2024–2025)
- Systematic review/meta-analysis: TMS for central post-stroke pain (Frontiers, 2024)
- 2024 meta-analysis: tDCS in fibromyalgia — pain intensity reduction and functional impact (ScienceDirect)
- 2025 umbrella review: tDCS in chronic pain — effectiveness in fibromyalgia, signals in migraine and neuropathic pain, methodological quality caveats (PMC)
- 2025 Pain Medicine review: M1 efficacy as a network effect, alternative targets (OUP Academic)
- tES safety guidelines 2017–2025: recommendations for low-intensity tDCS/tACS (IFCN)
Request a multidisciplinary assessment (Pain Unit + Physiotherapy/OT + Neuropsychology) and a combined plan proposal (neuromodulation + graded exercise + pain education) tailored to phenotype at GNeuro.